Clinical Trials | August 04, 2022
Merck and Eisai provide update on Phase 3 LEAP-002 trial evaluating KEYTRUDA
The safety profile of KEYTRUDA plus LENVIMA was consistent with previously reported data on the combination.
The safety profile of KEYTRUDA plus LENVIMA was consistent with previously reported data on the combination.
An algorithm based testing for Fatty Liver Disease
The product will be launched by NATCO's commercial partner Viatris.
SCG101 is an autologous T-cell receptor (TCR) T-cell therapy for liver cancer
CStone granted the exclusive rights to Hengrui for research, development, registration, manufacturing, and commercialization of anti-CTLA-4 mAb CS1002 in the Greater China region
The trial met the primary endpoint of overall survival with a single priming dose of tremelimumab plus Imfinzi every four weeks vs. sorafenib
_256_384.jpg)
In several trials like Celestial (double-blind phase III trial), Phase III Meteor trials, Cabozantinib has shown better PFS (Progression-Free Survival).
Partnership enables broad reach of cfDNA methylation blood tests for early cancer detection
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
